Combination Biologic Therapy Without Chemotherapy As Initial Treatment For Mantle Cell Lymphoma: Multi-Center Phase II Study Of Lenalidomide Plus Rituximab
Jia Ruan(Cornell University), John P. Leonard(New York University), Richard R. Furman(Cornell University), Paul J. Christos(Cornell University), Bijal Shah(Boston College), Peter Martin(Northwestern University), Stephen J. Schuster(Hospital of the University of Pennsylvania), Alison Bender(Cornell University), Morton Coleman(Cornell University), Paige W. Wolstencroft(Cornell University), Jakub Svoboda(UPMC Hillman Cancer Center), Jessica Lewis(Nanotherapeutics (United States)), Sonali M. Smith(University of Chicago)
Cited by 9
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k